» Articles » PMID: 31528833

Diagnostic Accuracy of the Aldosterone-to-Active Renin Ratio for Detecting Primary Aldosteronism

Abstract

Context: The aldosterone-to-active renin ratio (AARR) is the recommended screening test for primary aldosteronism (PA), but prospective study data on its sensitivity and specificity are sparse.

Objective: To investigate the diagnostic accuracy of the AARR for detecting PA.

Design: Prospective diagnostic accuracy study.

Setting: This study was conducted from February 2009 to August 2015 at the outpatient clinic of the Department of Endocrinology and Diabetology of the Medical University of Graz, Austria.

Participants: Four hundred patients with arterial hypertension who were referred to a tertiary care center for screening for endocrine hypertension.

Intervention: Participants had a determination of the AARR (index test) and a second AARR determination followed by a saline infusion test (SIT) after 2 to 6 weeks. PA was diagnosed in individuals with any AARR ≥3.7 ng/dL/µU/mL [including a plasma aldosterone concentration (PAC) of ≥9 ng/dL] who had a PAC ≥10 ng/dL after the SIT. We did not substantially alter antihypertensive drug intake.

Main Outcome Measures: Primary outcome was the receiver-operating characteristic (ROC) curve of the AARR in diagnosing PA.

Results: A total of 382 participants were eligible for analyses; PA was diagnosed in 18 (4.7%) patients. The area under the ROC curve of the AARR in detecting PA was 0.973 (95% CI, 0.956 to 0.990). Sensitivity and specificity for a positive AARR in diagnosing PA were 100% (95% CI, 81.5% to 100.0%) and 89.6% (95% CI, 86.0% to 92.5%), respectively.

Conclusions: The AARR has good diagnostic accuracy for detecting PA.

Citing Articles

Diagnostic efficacy of aldosterone-to-renin ratio to screen primary aldosteronism in hypertension: a systemic review and meta-analysis.

Kao T, Chen J, Liu J, Tseng W, Hsieh C, Wu V Ther Adv Endocrinol Metab. 2024; 15:20420188241303429.

PMID: 39669529 PMC: 11635879. DOI: 10.1177/20420188241303429.


Development of a diagnostic model for pre-washout screening of primary aldosteronism.

Wang Q, Dong H, Li H, Zheng Z, Liu Y, Hua Y J Endocrinol Invest. 2024; 47(10):2539-2550.

PMID: 38536656 PMC: 11393003. DOI: 10.1007/s40618-024-02337-y.


Performance of Aldosterone-to-renin Ratio Before Washout of Antihypertensive Drugs in Screening of Primary Aldosteronism.

Liu X, Hao S, Bian J, Lou Y, Zhang H, Wu H J Clin Endocrinol Metab. 2024; 109(12):e2302-e2308.

PMID: 38381080 PMC: 11570383. DOI: 10.1210/clinem/dgae094.


The Effect of Antihypertensive Medications on Testing for Primary Aldosteronism.

Jedrusik P, Symonides B, Lewandowski J, Gaciong Z Front Pharmacol. 2021; 12:684111.

PMID: 34054559 PMC: 8155700. DOI: 10.3389/fphar.2021.684111.

References
1.
Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J . Primary aldosteronism and hypertensive disease. Hypertension. 2003; 42(2):161-5. DOI: 10.1161/01.HYP.0000079505.25750.11. View

2.
Mulatero P, Stowasser M, Loh K, Fardella C, Gordon R, Mosso L . Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004; 89(3):1045-50. DOI: 10.1210/jc.2003-031337. View

3.
Calhoun D . Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis. 2006; 48(6):387-96. DOI: 10.1016/j.pcad.2006.02.002. View

4.
Schirpenbach C, Seiler L, Maser-Gluth C, Beuschlein F, Reincke M, Bidlingmaier M . Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem. 2006; 52(9):1749-55. DOI: 10.1373/clinchem.2006.068502. View

5.
Diederich S, Bidlingmaier M, Quinkler M, Reincke M . [Diagnosis of primary hyperaldosteronism]. Med Klin (Munich). 2007; 102(1):16-21. DOI: 10.1007/s00063-007-1002-y. View